Kwak Sang Gyu, Choo Yoo Jin, Chang Min Cheol
Department of Medical Statistics, College of Medicine, Catholic University of Daegu, Daegu, Korea.
Production R&D Division Advanced Interdisciplinary Team, Medical Device Development Center, Daegu-Gyeongbuk Medical Innovation, Daegu, Korea.
Pain Pract. 2022 Mar;22(3):381-390. doi: 10.1111/papr.13090. Epub 2021 Nov 25.
Many patients with complex regional pain syndrome (CRPS) experience refractory pain with severe restrictions in the activities of daily living. Oral prednisolone is commonly used to treat these patients.
To review previous studies assessing the effects of prednisolone in CRPS patients.
Articles published from January 1, 1980 to July 23, 2021 in the PubMed database were searched using the following key phrases: (prednisolone OR corticosteroid OR steroid) AND (complex regional pain syndrome OR reflex sympathetic dystrophy OR shoulder-hand syndrome OR causalgia). Specifically, we included those articles in which oral prednisolone or corticosteroids were used to control the CRPS symptoms.
In total, 11 articles were included, comprising 3 randomized trials, 5 single-arm prospective observational studies, and 3 retrospective studies. Nearly all previous studies reported that oral prednisolone can effectively control the CRPS symptoms. Moreover, though 30-100 mg/day of oral prednisolone was initially administered in these studies, 30 mg/day was also found to be effective in controlling the symptoms. Although prednisolone was usually administered for 1-3 months, short-term treatment for 1-2 weeks was also reportedly effective. Furthermore, only 0%-30% of the patients in these studies had minor side effects after prednisolone treatment.
Our review showed that prednisolone may be effective in alleviating the CRPS symptoms. To determine higher levels of evidence, a full systematic review with more highly qualified studies, such as randomized controlled trials, should be conducted in the future.
许多复杂性区域疼痛综合征(CRPS)患者经历难治性疼痛,日常生活活动受到严重限制。口服泼尼松龙常用于治疗这些患者。
回顾以往评估泼尼松龙对CRPS患者疗效的研究。
使用以下关键词搜索1980年1月1日至2021年7月23日在PubMed数据库中发表的文章:(泼尼松龙或皮质类固醇或类固醇)和(复杂性区域疼痛综合征或反射性交感神经营养不良或肩手综合征或灼性神经痛)。具体而言,我们纳入了那些使用口服泼尼松龙或皮质类固醇来控制CRPS症状的文章。
总共纳入11篇文章,包括3项随机试验、5项单臂前瞻性观察研究和3项回顾性研究。几乎所有以往研究均报告口服泼尼松龙可有效控制CRPS症状。此外,尽管这些研究最初给予30 - 100毫克/天的口服泼尼松龙,但发现30毫克/天也能有效控制症状。虽然泼尼松龙通常给药1 - 3个月,但据报道短期治疗1 - 2周也有效。此外,这些研究中只有0% - 30%的患者在泼尼松龙治疗后有轻微副作用。
我们的综述表明,泼尼松龙可能有效缓解CRPS症状。为了确定更高水平的证据,未来应进行更具高质量研究的全面系统综述,如随机对照试验。